Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 4
---
 candidates;                                                             |

| ● | the                                                                                           
 accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs 
 for additional financing;                                                                     |

| ● | the                                                                                       
 scope, progress, results and costs of developing CER-1236 or any other product candidates 
 we may develop, and conducting preclinical studies and clinical trials;                   |

| ● | the                                                                                             
 timing and costs involved in obtaining and maintaining regulatory approval of CER-1236 or       
 any other product candidates we may develop, and the timing or likelihood of regulatory filings 
 and approvals, including our expectation to seek special designations or accelerated approvals  
 for our drug candidates for various indications;                                                |

| ● | current                                                                                           
 and future agreements with third parties in connection with the development and commercialization 
 of CER-1236 or any other future product candidate;                                                |

| ● | our                                                                                   
 ability to advance product candidates into and successfully complete clinical trials; |

| ● | the                                                                                       
 ability of our clinical trials to demonstrate the safety and efficacy of CER-1236 and any 
 other product candidates we may develop, and other positive results;                      |

<div align='center'>ii</div>

| ● | the                                                                                           
 size and growth potential of the markets for our product candidates, and our ability to serve 
 those markets;                                                                                |

| ● | the benefits of orphan drug designation                                                                                            
 and potential for orphan drug exclusivity in the future for CER-1236 and any other product candidates that may receive orphan drug 
 designation;                                                                                                                       |

| ● | our                                                                                           
 plans relating to the commercialization of CER-1236 and any other product candidates we may   
 develop, if approved, including the geographic areas of focus and our ability to grow a sales 
 team;                                                                                         |

| ● | the                                                                                       
 success of competing drugs, therapies or other products that are or may become available; |

| ● | developments                                                                             
 relating to our competitors and our industry, including competing product candidates and 
 therapies;                                                                               |

| ● | our                                                                                           
 plans relating to the further development and manufacturing of CER-1236 and any other product 
 candidates we may develop, including additional indications that we may pursue for CER-1236   
 or other product candidates;                                                                  |

| ● | existing                                                                              
 regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our                                                                                         
 potential and ability to successfully manufacture and supply CER-1236 and any other product 
 candidates we may develop for clinical